INCY vs SMMT
INCY: Incyte is a biopharmaceutical company focused on discovering and developing innovative medicines for oncology and inflammatory conditions. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | INCY | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $118.87 | $13.10 | |
| Market cap as of 2026-07-29 | $25.8B | $10.2B | |
| P/E as of 2026-07-29 | 16.81 | n/a | |
| PEG as of 2026-07-29 | 1.00 | -1.06 | SMMT lower |
| Net margin as of 2026-07-29 | +26.7% | -9027.1% | INCY higher |
| Gross margin as of 2026-07-29 | +93.0% | n/a | |
| Operating margin as of 2026-07-29 | +30.1% | -8108.3% | INCY higher |
| ROE as of 2026-07-29 | +29.2% | -168.9% | INCY higher |
| ROA as of 2026-07-29 | +21.6% | -141.9% | INCY higher |
| Debt / equity as of 2026-07-29 | 0.01 | 0.00 | SMMT lower |
| Revenue growth (YoY) as of 2026-07-29 | +21.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +14.8% | n/a | |
| Beta as of 2026-07-29 | 0.75 | -1.33 | |
| 1-year return as of 2026-07-27 close | +69.3% | -54.3% | INCY higher |
Fundamentals: market data, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.